Verheugt F W, ten Cate J W, Sturk A, Imandt L, Verhorst P M, van Eenige M J, Verwey W, Roos J P
Am J Cardiol. 1987 May 1;59(12):1075-9. doi: 10.1016/0002-9149(87)90851-4.
Parameters of blood coagulation, blood platelet reactivity and fibrinolysis were analyzed in 18 patients with acute myocardial infarction (AMI) and angiographically normal coronary arteries. This study group was compared with a patient control group of 18 AMI patients with 1-vessel obstructive coronary artery disease. Patients were matched for sex, age and AMI date. A healthy control group consisted of 18 sex- and age-matched volunteers. Blood coagulation measurements and platelet reactivity were similar in the 3 groups, except for fibrinogen, which was significantly higher in the patient control group. Plasma activity of tissue plasminogen activator (tPA) was detectable in only 2 patients in the study group, 9 in the patient control group (p less than 0.02) and 12 in the healthy control group (p less than 0.0001). Median plasma tPA inhibitory activity was higher in the study group (10.3 IU/ml) and the patient control group (8.1 IU/ml) than in the healthy control group (2.7 IU/ml, p less than 0.0001 and p less than 0.03). Thus, reduced activity and enhanced inhibition of plasma tPA may be important factors in the origin of coronary thrombosis, especially in the absence of coronary artery disease.
对18例急性心肌梗死(AMI)且冠状动脉造影正常的患者的凝血、血小板反应性和纤维蛋白溶解参数进行了分析。该研究组与18例患有单支血管阻塞性冠状动脉疾病的AMI患者组成的对照患者组进行了比较。患者在性别、年龄和AMI日期方面进行了匹配。一个健康对照组由18名年龄和性别匹配的志愿者组成。除纤维蛋白原外,三组的凝血测量和血小板反应性相似,纤维蛋白原在对照患者组中显著更高。研究组中仅2例患者可检测到组织纤溶酶原激活剂(tPA)的血浆活性,对照患者组中有9例(p<0.02),健康对照组中有12例(p<0.0001)。研究组(10.3 IU/ml)和对照患者组(8.1 IU/ml)的血浆tPA抑制活性中位数高于健康对照组(2.7 IU/ml,p<0.0001和p<0.03)。因此,血浆tPA活性降低和抑制增强可能是冠状动脉血栓形成的重要因素,尤其是在无冠状动脉疾病的情况下。